Mitchell Kamrava

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8016187/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	American Brachytherapy Society radiation oncology alternative payment model task force: Quality measures and metrics for brachytherapy. Brachytherapy, 2022, 21, 63-74.	0.5	3
2	Driving accountable care with brachytherapy. Brachytherapy, 2022, 21, 4-5.	0.5	0
3	Evaluation of sociodemographic and baseline patient characteristic differences in cervical cancer patients treated with either external beam or brachytherapy boost. Brachytherapy, 2022, 21, 22-28.	0.5	2
4	Chemotherapy predictors and a time-dependent chemotherapy effect in metastatic esophageal cancer. World Journal of Gastrointestinal Oncology, 2022, 14, 511-524.	2.0	1
5	Pathologic primary tumor factors associated with risk of lymph node involvement in patients with non-endometrioid endometrial cancer. Gynecologic Oncology, 2022, , .	1.4	Ο
6	Quantitative Nodal Burden and Mortality Across Solid Cancers. Journal of the National Cancer Institute, 2022, 114, 1003-1011.	6.3	4
7	Evaluation of burnout in physician members of the American Brachytherapy Society. Brachytherapy, 2022, 21, 362-368.	0.5	1
8	Evaluation of patterns of progression on poly (ADP-ribose) polymerase inhibitor (PARPi) maintenance in ovarian cancer: a cross-sectional study. International Journal of Gynecological Cancer, 2022, 32, 153-158.	2.5	2
9	In Regard to Apisarnthanarax et al. Practical Radiation Oncology, 2022, 12, e239.	2.1	1
10	Evaluation of Mobile Health Applications to Track Patient-Reported Outcomes for Oncology Patients: A Systematic Review. Advances in Radiation Oncology, 2021, 6, 100576.	1.2	42
11	High-dose-rate fractionated brachytherapy monotherapy for localized prostate cancer: a systematic review and meta-analysis. Journal of Contemporary Brachytherapy, 2021, 13, 365-372.	0.9	6
12	Interstitial high-dose-rate brachytherapy in the treatment of keloids: Moving toward a volumetric approach. Brachytherapy, 2021, 20, 185-188.	0.5	3
13	Interstitial brachytherapy for gynecologic malignancies: Complications, toxicities, and management. Brachytherapy, 2021, 20, 995-1004.	0.5	8
14	Integrating PARP Inhibitors Into Advanced Prostate Cancer Therapeutics. Oncology, 2021, 35, 119-125.	0.5	5
15	Red Blood Cell Transfusion Practices for Patients With Cervical Cancer Undergoing Radiotherapy. JAMA Network Open, 2021, 4, e213531.	5.9	6
16	Paid Parental Leave Policies Among U.S. News & World Report 2020-2021 Best Hospitals and Best Hospitals for Cancer. JAMA Network Open, 2021, 4, e218518.	5.9	9
17	Prediction of soft tissue sarcoma response to radiotherapy using longitudinal diffusion MRI and a deep neural network with generative adversarial networkâ€based data augmentation. Medical Physics, 2021, 48, 3262-3372.	3.0	11
18	Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer. PLoS ONE, 2021, 16, e0252665.	2.5	13

#	Article	IF	CITATIONS
19	Hypofractionated radiation therapy and wound healing after massive sarcoma resection: Case report and review of the literature. International Journal of Surgery Case Reports, 2021, 83, 106005.	0.6	3
20	Outcomes with multi-disciplinary management of central lung tumors with CT-guided percutaneous high dose rate brachyablation. Radiation Oncology, 2021, 16, 99.	2.7	4
21	American Brachytherapy Society (ABS) consensus statement for soft-tissue sarcoma brachytherapy. Brachytherapy, 2021, 20, 1200-1218.	0.5	4
22	ACR–ABS–ASTRO practice parameter for the performance of radionuclide-based high-dose-rate brachytherapy. Brachytherapy, 2021, 20, 1071-1082.	0.5	5
23	Socioeconomic and Racial Determinants of Brachytherapy Utilization for Cervical Cancer: Concerns for Widening Disparities. JCO Oncology Practice, 2021, 17, e1958-e1967.	2.9	19
24	Re: Jana S. Hopstaken, Joyce G.R. Bomers, Michiel J.P. Sedelaar, Massimo Valerio, Jurgen J. Fütterer, Maroeska M. Rovers. An Updated Systematic Review on Focal Therapy in Localized Prostate Cancer: What Has Changed over the Past 5 Years? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.08.005. European Urology, 2021, , .	1.9	0
25	A Comparison of Clinicopathologic Outcomes Across Neoadjuvant and Adjuvant Treatment Modalities in Resectable Gastric Cancer. JAMA Network Open, 2021, 4, e2138432.	5.9	8
26	Glaucoma After Iodine-125 Brachytherapy for Uveal Melanoma: Incidence and Risk Factors. Journal of Glaucoma, 2020, 29, 1-10.	1.6	14
27	The ASTRO clinical practice guidelines in cervical cancer: Optimizing radiation therapy for improved outcomes. Gynecologic Oncology, 2020, 159, 607-610.	1.4	23
28	Evaluating reimbursement of skin radiation therapy: Technique and fractionation. Brachytherapy, 2020, 19, 700-704.	0.5	1
29	The American Brachytherapy society consensus statement for skin brachytherapy. Brachytherapy, 2020, 19, 415-426.	0.5	28
30	Clinical Development and Evaluation of Megavoltage Topogram for Fast Patient Alignment on Helical Tomotherapy. Advances in Radiation Oncology, 2020, 5, 1334-1341.	1.2	1
31	Proposed brachytherapy recommendations (practical implementation, indications, and dose) Tj ETQq1 1 0.7843	14 rgBT /C	Overlock 10 The 13 13
32	Radiation Therapy for Cervical Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. Practical Radiation Oncology, 2020, 10, 220-234.	2.1	144
33	American Brachytherapy Society working group report on the patterns of care and a literature review of reirradiation for gynecologic cancers. Brachytherapy, 2020, 19, 127-138.	0.5	19
34	A dosimetric evaluation of a single urethral constraint for high-dose-rate prostate brachytherapy. Brachytherapy, 2020, 19, 216-221.	0.5	5
35	SAbR as an Alternative Boost Modality for Cervical Cancer: A Cautionary Exercise. International Journal of Radiation Oncology Biology Physics, 2020, 106, 472-474.	0.8	4
36	Impact of palliative therapies in metastatic esophageal cancer patients not receiving chemotherapy. World Journal of Gastrointestinal Surgery, 2020, 12, 377-389.	1.5	3

#	Article	IF	CITATIONS
37	Impact of palliative care in patients with metastatic esophageal cancer declining chemotherapy Journal of Clinical Oncology, 2020, 38, 315-315.	1.6	0
38	The impact of neoadjuvant and/or adjuvant treatment modalities in resectable gastric cancer (rGC) Journal of Clinical Oncology, 2020, 38, e16564-e16564.	1.6	0
39	Baseline features predicting receipt of chemotherapy in metastatic esophageal cancer: A National Cancer Database analysis of 12,370 patients Journal of Clinical Oncology, 2020, 38, 316-316.	1.6	0
40	Extent of lymph node resection and effect on pancreatic cancer overall survival Journal of Clinical Oncology, 2020, 38, 682-682.	1.6	0
41	A radiopaque polymer hydrogel as an irreversible electroporation compatible fiducial marker for pancreas stereotactic body radiotherapy. Journal of Radiosurgery and SBRT, 2020, 7, 165-167.	0.2	Ο
42	In Regard to Peters etÂal. International Journal of Radiation Oncology Biology Physics, 2019, 104, 1182-1183.	0.8	1
43	Letter to the Editor Regarding: Prospective Comparison of Toxicity and Cosmetic Outcome After Accelerated Partial Breast Irradiation with Conformal External Beam Radiotherapy or Single-Entry Multilumen Intracavitary Brachytherapy. Practical Radiation Oncology, 2019, 9, 59.	2.1	1
44	Prostate Cancer Radiotherapy: An Evolving Paradigm That Should Also Include High-Dose-Rate Monotherapy. Journal of Clinical Oncology, 2019, 37, 441-441.	1.6	2
45	Oncogenic Y68 frame shift mutation of PTEN represents a mechanism of docetaxel resistance in endometrial cancer cell lines. Scientific Reports, 2019, 9, 2111.	3.3	14
46	A proposal for a new classification of "unfavorable risk criteria―in patients with stage I endometrial cancer. International Journal of Gynecological Cancer, 2019, 29, 1086-1093.	2.5	6
47	An evaluation of gender diversity in the American Brachytherapy Society. Brachytherapy, 2019, 18, 835-840.	0.5	Ο
48	Brachytherapy Training Survey of Radiation Oncology Residents. International Journal of Radiation Oncology Biology Physics, 2019, 103, 557-560.	0.8	77
49	The American Brachytherapy Society consensus statement for electronic brachytherapy. Brachytherapy, 2019, 18, 292-298.	0.5	23
50	Preoperative CA 19-9 and CEA as predictors of operative outcomes in resectable gastric cancer (GC) Journal of Clinical Oncology, 2019, 37, e15581-e15581.	1.6	0
51	Long-term Outcomes With Ifosfamide-based Hypofractionated Preoperative Chemoradiotherapy for Extremity Soft Tissue Sarcomas. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 1154-1161.	1.3	35
52	Clinical outcomes using image-guided interstitial brachytherapy for definitive cervical cancer patients with high-risk clinical target volumes greater than 30Acc. Brachytherapy, 2018, 17, 392-398.	0.5	9
53	Underutilization of brachytherapy and disparities in survival for patients with cervical cancer in California. Gynecologic Oncology, 2018, 150, 73-78.	1.4	35
54	Head and neck cancer reirradiation with interstitial highâ€doseâ€rate brachytherapy. Head and Neck, 2018, 40, 1524-1533.	2.0	14

#	Article	IF	CITATIONS
55	NEW ULTRA–WIDE-FIELD ANGIOGRAPHIC GRADING SCHEME FOR RADIATION RETINOPATHY AFTER IODINE-125 BRACHYTHERAPY FOR UVEAL MELANOMA. Retina, 2018, 38, 2415-2421.	1.7	16
56	Comparison of patientâ€reported acute urinary and sexual toxicity scores in a 6―versus 2â€fraction course of highâ€doseâ€rate prostate brachytherapy monotherapy. Journal of Medical Imaging and Radiation Oncology, 2018, 62, 109-115.	1.8	4
57	Outcomes of Node-positive Breast Cancer Patients Treated With Accelerated Partial Breast Irradiation Via Multicatheter Interstitial Brachytherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 538-543.	1.3	4
58	Predicting the necessity of adding catheters to intracavitary brachytherapy for women undergoing definitive chemoradiation for locally advanced cervical cancer. Brachytherapy, 2018, 17, 935-943.	0.5	6
59	Pattern of solid and hematopoietic second malignancy after local therapy for prostate cancer. Radiotherapy and Oncology, 2017, 123, 133-138.	0.6	12
60	Juxtapapillary and circumpapillary choroidal melanoma: globe-sparing treatment outcomes with iodine-125 notched plaque brachytherapy. Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255, 1843-1850.	1.9	11
61	External Beam Radiation Therapy With a Brachytherapy Boost Versus Radical Prostatectomy in Gleason Pattern 5 Prostate Cancer: A Population-Based Cohort Study. International Journal of Radiation Oncology Biology Physics, 2017, 98, 1045-1052.	0.8	12
62	Long term results from a prospective database on high dose rate (HDR) interstitial brachytherapy for primary cervical carcinoma. Gynecologic Oncology, 2017, 144, 21-27.	1.4	12
63	High-dose-rate brachytherapy monotherapy without androgen deprivation therapy for intermediate-risk prostate cancer. Brachytherapy, 2017, 16, 299-305.	0.5	18
64	Pretreatment 3T multiparametric MRI staging predicts for biochemical failure in high-risk prostate cancer treated with combination high-dose-rate brachytherapy and external beam radiotherapy. Brachytherapy, 2017, 16, 1106-1112.	0.5	19
65	American Brachytherapy Society recurrent carcinoma of the endometrium task force patterns of care and review of the literature. Brachytherapy, 2017, 16, 1129-1143.	0.5	25
66	Distortionâ€free diffusion <scp>MRI</scp> using an <scp>MRI</scp> â€guided Triâ€Cobalt 60 radiotherapy system: Sequence verification and preliminary clinical experience. Medical Physics, 2017, 44, 5357-5366.	3.0	31
67	American Brachytherapy Society consensus report for accelerated partial breast irradiation using interstitial multicatheter brachytherapy. Brachytherapy, 2017, 16, 919-928.	0.5	31
68	Clinical Outcomes for Patients with Gleason Score 9–10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. European Urology, 2017, 71, 766-773.	1.9	83
69	Enhanced skin toxicity with concurrent ipilimumab and radiation in vaginal/vulvar melanoma: a case report and literature review. BJR case Reports, 2017, 3, 20160002.	0.2	1
70	Imaging and Pathology Correlations for Different Risk Stratification Models for Intermediate-risk Prostate Cancer. Anticancer Research, 2017, 37, 1237-1242.	1.1	1
71	Another solution that enables ablative radiotherapy for large liver tumors: Percutaneous interstitial highâ€dose rate brachytherapy. Cancer, 2016, 122, 2766-2766.	4.1	3
72	Locoregional recurrence by molecular subtype after multicatheter interstitial accelerated partial breast irradiation: Results from the Pooled Registry Of Multicatheter Interstitial Sites research group. Brachytherapy, 2016, 15, 788-795.	0.5	14

#	Article	IF	CITATIONS
73	Real-time image guidance for gynecologic brachytherapy?. Radiotherapy and Oncology, 2016, 120, 542-543.	0.6	1
74	Intensity modulated radiation therapy for women with gynecologic cancers: this horse is also already out of the barn. Gynecologic Oncology, 2016, 143, 1-2.	1.4	2
75	23-mm iodine-125 plaque for uveal melanoma: benefit of vitrectomy and silicone oil on visual acuity. Graefe's Archive for Clinical and Experimental Ophthalmology, 2016, 254, 2461-2467.	1.9	11
76	Pre-treatment MRI minimum apparent diffusion coefficient value is a potential prognostic imaging biomarker in cervical cancer patients treated with definitive chemoradiation. BMC Cancer, 2016, 16, 556.	2.6	27
77	Tumor-height regression rate after brachytherapy between choroidal melanoma gene expression profile classes: effect of controlling for tumor height. Graefe's Archive for Clinical and Experimental Ophthalmology, 2016, 254, 1371-1378.	1.9	12
78	Utilizing timeâ€driven activityâ€based costing to understand the short―and longâ€term costs of treating localized, lowâ€risk prostate cancer. Cancer, 2016, 122, 447-455.	4.1	123
79	Does the addition of targeted prostate biopsies to standard systemic biopsies influence treatment management for radiation oncologists?. BJU International, 2016, 117, 584-591.	2.5	6
80	SBRT and HDR brachytherapy produce lower PSA nadirs and different PSA decay patterns than conventionally fractionated IMRT in patients with low- or intermediate-risk prostate cancer. Practical Radiation Oncology, 2016, 6, 268-275.	2.1	27
81	A sector-based dosimetric analysis of dose heterogeneity in high-dose-rate prostate brachytherapy. Brachytherapy, 2015, 14, 173-178.	0.5	1
82	Outcomes of Breast Cancer Patients Treated with Accelerated Partial Breast Irradiation Via Multicatheter Interstitial Brachytherapy: The Pooled Registry of Multicatheter Interstitial Sites (PROMIS) Experience. Annals of Surgical Oncology, 2015, 22, 404-411.	1.5	26
83	Early clinical outcomes of ultrasound-guided CT-planned high-dose-rate interstitial brachytherapy for primary locally advanced cervical cancer. Brachytherapy, 2015, 14, 626-632.	0.5	13
84	The ideal adjuvant treatment in node positive vulvar cancer is (fill in your best guess here). Gynecologic Oncology, 2015, 137, 363-364.	1.4	1
85	Re: Ian A. Donaldson, Roberto Alonzi, Dean Barratt, et al. Focal Therapy: Patients, Interventions, and Outcomes—A Report from a Consensus Meeting. Eur Urol 2015;67:771–7. European Urology, 2015, 68, e14.	1.9	2
86	Multiparametric magnetic resonance imaging for prostate cancer improves Gleason score assessment in favorable risk prostate cancer. Practical Radiation Oncology, 2015, 5, 411-416.	2.1	25
87	Quantitative multiparametric MRI in uveal melanoma: increased tumor permeability may predict monosomy 3. Neuroradiology, 2015, 57, 833-840.	2.2	22
88	Dosimetric benefits of hemigland stereotactic body radiotherapy for prostate cancer: implications for focal therapy. British Journal of Radiology, 2015, 88, 20150658.	2.2	5
89	In Regard to Mishra etÂal. International Journal of Radiation Oncology Biology Physics, 2015, 93, 216.	0.8	2
90	Dosimetric feasibility of magnetic resonance imagingâ€guided tri-cobalt 60 preoperative intensity modulated radiation therapy for soft tissue sarcomas of the extremity. Practical Radiation Oncology, 2015, 5, 350-356.	2.1	8

#	Article	IF	CITATIONS
91	Potential role of ultrasound imaging in interstitial image based cervical cancer brachytherapy. Journal of Contemporary Brachytherapy, 2014, 2, 223-230.	0.9	20
92	Multiparametric MRI identifies and stratifies prostate cancer lesions: Implications for targeting intraprostatic targets. Brachytherapy, 2014, 13, 292-298.	0.5	12
93	Brachytherapy in the treatment of cervical cancer: a review. International Journal of Women's Health, 2014, 6, 555.	2.6	80
94	Focal high-dose-rate brachytherapy: A dosimetric comparison of hemigland vs. conventional whole-gland treatment. Brachytherapy, 2013, 12, 434-441.	0.5	25
95	Quantifying the Ki-67 Heterogeneity Profile in Prostate Cancer. Prostate Cancer, 2013, 2013, 1-5.	0.6	15